The Journal of Pharmacology and Experimental Therapeutics

The Journal of Pharmacology and Experimental Therapeutics
Title	The Journal of Pharmacology and Experimental Therapeutics
Discipline	Pharmacology
Abbreviation	J. Pharmacol. Exp. Ther.
Publisher	American Society for Pharmacology and Experimental Therapeutics
Country	United States
History	1909–present
Frequency	Monthly
Issn	0022-3565

The Journal of Pharmacology and Experimental Therapeutics is a peer-reviewed scientific periodical publishing research in pharmacology and experimental therapeutics, affiliated with the American Society for Pharmacology and Experimental Therapeutics, the National Institutes of Health, and other biomedical organizations. The journal serves researchers linked to institutions such as Columbia University, Harvard University, Johns Hopkins University, Yale University, and the University of Oxford, and receives submissions from laboratories connected to the National Institutes of Health, Centers for Disease Control and Prevention, and pharmaceutical companies including Pfizer, GlaxoSmithKline, Merck, Novartis, and AstraZeneca.

History

The journal was established in 1909 during a period of expansion in biomedical publishing that included contemporaries like The Lancet, Journal of the American Medical Association, and Proceedings of the Royal Society, with editorial leadership drawing on figures affiliated with the Rockefeller Institute, Massachusetts General Hospital, and University of Pennsylvania. Over decades the journal intersected with milestones at institutions such as the Mayo Clinic, Walter Reed Army Medical Center, and Cold Spring Harbor Laboratory, while publishing work by investigators connected to the Royal Society, Max Planck Society, and Karolinska Institutet. During the World Wars and the postwar era the journal reflected scientific shifts occurring at the Pasteur Institute, Imperial College London, and the University of Cambridge, and later featured research related to developments at the Food and Drug Administration and European Medicines Agency. Through the late 20th and early 21st centuries the journal engaged with trends emerging from Stanford University, Massachusetts Institute of Technology, University of California San Francisco, and the Salk Institute.

Scope and Content

The journal publishes original research articles, reviews, and commentaries reporting experimental results from laboratories at institutions including Rockefeller University, Duke University, University of Michigan, Columbia University, and University College London, with topics spanning receptor pharmacology, signal transduction, ion channel biology, enzymology, and drug metabolism as studied by investigators affiliated with the National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute of Neurological Disorders and Stroke. Contributions often involve collaborative networks tied to the Howard Hughes Medical Institute, Wellcome Trust, Medical Research Council, and European Research Council, and include work relevant to clinical centers such as Cleveland Clinic, Mount Sinai Health System, and Mayo Clinic. The journal has featured research employing techniques developed at institutions like Cold Spring Harbor Laboratory, EMBL, and Scripps Research, and reports findings that inform policy and practice at agencies including the World Health Organization and Veterans Health Administration.

Publication and Access

Published monthly by the American Society for Pharmacology and Experimental Therapeutics, the journal operates alongside sibling publications associated with professional societies such as the American Chemical Society and British Pharmacological Society, and maintains distribution channels through university presses at Oxford University Press, Cambridge University Press, and Yale University Press. Access policies have evolved in dialogue with funders such as the Wellcome Trust, Bill & Melinda Gates Foundation, Howard Hughes Medical Institute, and institutions like the National Institutes of Health and European Commission, and the journal participates in initiatives related to open access models used by PLOS, eLife, and BioMed Central. Subscriptions are held by libraries at Harvard Library, Bodleian Libraries, Library of Congress, and Bibliothèque nationale de France, and the journal is available via platforms used by JSTOR, PubMed Central, and Scopus.

Editorial Board and Peer Review

Editorial oversight has involved editors and advisory board members who have affiliations with universities and organizations including Yale University, Harvard Medical School, University of California Berkeley, University of Pennsylvania, and Rockefeller University, and peer reviewers are drawn from networks at institutions such as Columbia University, University of Chicago, University of Toronto, Karolinska Institutet, and Max Planck Society. The peer review process aligns with standards promoted by the Committee on Publication Ethics, International Committee of Medical Journal Editors, and National Academies of Sciences, Engineering, and Medicine, and editorial practices reflect guidelines used by The New England Journal of Medicine, Nature, and Science. Guest editors and special issues have been coordinated with centers at Stanford University, Massachusetts General Hospital, and University College London.

Abstracting and Indexing

The journal is indexed in major bibliographic databases and services utilized by researchers at institutions such as the National Institutes of Health, European Molecular Biology Laboratory, and Chinese Academy of Sciences, including indexing in PubMed, MEDLINE, Web of Science, Scopus, and Embase, and cataloged in library systems like WorldCat and Library of Congress. Citation tracking by Clarivate Analytics, Elsevier, and Google Scholar registers articles alongside outputs from journals such as Nature Medicine, Cell, Journal of Clinical Investigation, and Proceedings of the National Academy of Sciences.

Notable Articles and Impact

Over its history the journal has published influential articles by investigators associated with institutions such as the Rockefeller Institute, University of Oxford, Harvard University, and Stanford University that contributed to understanding of adrenergic receptors, opioid pharmacology, calcium channel function, cytochrome P450 enzymology, and G protein–coupled receptor signaling, and those works have been cited alongside landmark studies in journals such as Nature, Science, and The Lancet. The journal’s impact has been measured by citation metrics compiled by Clarivate and Elsevier and has influenced drug discovery programs at companies including Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis, while shaping translational research initiatives at the National Institutes of Health, Veterans Affairs, and major academic medical centers.

Category:Pharmacology journals